Mechanism of troglitazone action in type 2 diabetes - PubMed (original) (raw)
Mechanism of troglitazone action in type 2 diabetes
K F Petersen et al. Diabetes. 2000 May.
Abstract
To examine the metabolic pathways by which troglitazone improves insulin responsiveness in patients with type 2 diabetes, the rate of muscle glycogen synthesis was measured by 13C-nuclear magnetic resonance (NMR) spectroscopy. The rate-controlling steps of insulin-stimulated muscle glucose metabolism were assessed using 31P-NMR spectroscopic measurement of intramuscular glucose-6-phosphate (G-6-P) combined with a novel 13C-NMR method to assess intracellular glucose concentrations. Seven healthy nonsmoking subjects with type 2 diabetes were studied before and after completion of 3 months of troglitazone (400 mg/day) therapy. After troglitazone treatment, rates of insulin-stimulated whole-body glucose uptake increased by 58+/-11%, from 629+/-82 to 987+/-156 micromol x m(-2) x min(-1) (P = 0.008), which was associated with an approximately 3-fold increase in rates of insulin-stimulated glucose oxidation (from 119+/-41 to 424+/-70 micromol x m(-2) x min(-1); P = 0.018) and muscle glycogen synthesis (26+/-17 vs. 83+/-35 micromol x l(-1) muscle x min(-1); P = 0.025). After treatment, muscle G-6-P concentrations increased by 0.083+/-0.019 mmol/l (P = 0.008 vs. pretreatment) during the hyperglycemic-hyperinsulinemic clamp, compared with no significant changes in intramuscular G-6-P concentrations in the pretreatment study, reflecting an improvement in glucose transport and/or hexokinase activity. The concentrations of intracellular free glucose did not differ between the pre- and posttreatment studies and remained >50-fold lower in concentration (<0.1 mmol/l) than what would be expected if hexokinase activity was rate-controlling. These results indicate that troglitazone improves insulin responsiveness in skeletal muscle of patients with type 2 diabetes by facilitating glucose transport activity, which thereby leads to increased rates of muscle glycogen synthesis and glucose oxidation.
Similar articles
- Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Yokoyama I, Yonekura K, Moritan T, Tateno M, Momose T, Ohtomo K, Inoue Y, Nagai R. Yokoyama I, et al. J Nucl Med. 2001 Jul;42(7):1005-10. J Nucl Med. 2001. PMID: 11438619 - Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB. Kim YB, et al. Diabetes. 2002 Feb;51(2):443-8. doi: 10.2337/diabetes.51.2.443. Diabetes. 2002. PMID: 11812753 Clinical Trial. - Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Kruszynska YT, et al. Diabetes. 2000 Apr;49(4):633-9. doi: 10.2337/diabetes.49.4.633. Diabetes. 2000. PMID: 10871202 - Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL, Faulds D. Plosker GL, et al. Drugs. 1999 Mar;57(3):409-38. doi: 10.2165/00003495-199957030-00014. Drugs. 1999. PMID: 10193691 Review. - Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Johnson MD, Campbell LK, Campbell RK. Johnson MD, et al. Ann Pharmacother. 1998 Mar;32(3):337-48. doi: 10.1345/aph.17046. Ann Pharmacother. 1998. PMID: 9533065 Review.
Cited by
- The role of peroxisome proliferator-activated receptors in the modulation of hyperinflammation induced by SARS-CoV-2 infection: A perspective for COVID-19 therapy.
Hasankhani A, Bahrami A, Tavakoli-Far B, Iranshahi S, Ghaemi F, Akbarizadeh MR, Amin AH, Abedi Kiasari B, Mohammadzadeh Shabestari A. Hasankhani A, et al. Front Immunol. 2023 Feb 17;14:1127358. doi: 10.3389/fimmu.2023.1127358. eCollection 2023. Front Immunol. 2023. PMID: 36875108 Free PMC article. Review. - Current Perspectives on Management of Type 2 Diabetes in Youth.
Singhal S, Kumar S. Singhal S, et al. Children (Basel). 2021 Jan 10;8(1):37. doi: 10.3390/children8010037. Children (Basel). 2021. PMID: 33435250 Free PMC article. Review. - Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study.
Cho YK, Lee J, Kim HS, Park JY, Jung CH, Lee WJ. Cho YK, et al. Diabetes Ther. 2020 Sep;11(9):2029-2039. doi: 10.1007/s13300-020-00881-3. Epub 2020 Jul 21. Diabetes Ther. 2020. PMID: 32696268 Free PMC article. - Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes.
Goedeke L, Perry RJ, Shulman GI. Goedeke L, et al. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:65-87. doi: 10.1146/annurev-pharmtox-010716-104727. Annu Rev Pharmacol Toxicol. 2019. PMID: 30625285 Free PMC article. Review. - Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.
Samuel VT, Shulman GI. Samuel VT, et al. Cell Metab. 2018 Jan 9;27(1):22-41. doi: 10.1016/j.cmet.2017.08.002. Epub 2017 Aug 31. Cell Metab. 2018. PMID: 28867301 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous